Kiora Pharmaceuticals (KPRX) Competitors $3.31 +0.02 (+0.61%) (As of 11:02 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends KPRX vs. LEXX, ATNM, SCYX, CALC, RLYB, LUMO, OCX, BIVI, TPST, and OKYOShould you be buying Kiora Pharmaceuticals stock or one of its competitors? The main competitors of Kiora Pharmaceuticals include Lexaria Bioscience (LEXX), Actinium Pharmaceuticals (ATNM), SCYNEXIS (SCYX), CalciMedica (CALC), Rallybio (RLYB), Lumos Pharma (LUMO), OncoCyte (OCX), BioVie (BIVI), Tempest Therapeutics (TPST), and OKYO Pharma (OKYO). These companies are all part of the "pharmaceutical products" industry. Kiora Pharmaceuticals vs. Lexaria Bioscience Actinium Pharmaceuticals SCYNEXIS CalciMedica Rallybio Lumos Pharma OncoCyte BioVie Tempest Therapeutics OKYO Pharma Kiora Pharmaceuticals (NASDAQ:KPRX) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation, community ranking and profitability. Does the MarketBeat Community favor KPRX or LEXX? Kiora Pharmaceuticals received 11 more outperform votes than Lexaria Bioscience when rated by MarketBeat users. However, 100.00% of users gave Lexaria Bioscience an outperform vote while only 73.91% of users gave Kiora Pharmaceuticals an outperform vote. CompanyUnderperformOutperformKiora PharmaceuticalsOutperform Votes1773.91% Underperform Votes626.09% Lexaria BioscienceOutperform Votes6100.00% Underperform VotesNo Votes Which has preferable earnings and valuation, KPRX or LEXX? Lexaria Bioscience has lower revenue, but higher earnings than Kiora Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiora Pharmaceuticals$16M0.62-$12.51MN/AN/ALexaria Bioscience$464.28K81.95-$5.80M-$0.47-4.64 Which has more volatility & risk, KPRX or LEXX? Kiora Pharmaceuticals has a beta of -0.44, indicating that its stock price is 144% less volatile than the S&P 500. Comparatively, Lexaria Bioscience has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Do insiders & institutionals believe in KPRX or LEXX? 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 0.9% of Kiora Pharmaceuticals shares are held by company insiders. Comparatively, 26.4% of Lexaria Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is KPRX or LEXX more profitable? Kiora Pharmaceuticals has a net margin of 0.00% compared to Lexaria Bioscience's net margin of -1,249.14%. Kiora Pharmaceuticals' return on equity of 21.32% beat Lexaria Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Kiora PharmaceuticalsN/A 21.32% 16.39% Lexaria Bioscience -1,249.14%-86.10%-80.32% Do analysts prefer KPRX or LEXX? Kiora Pharmaceuticals currently has a consensus price target of $10.00, suggesting a potential upside of 202.11%. Lexaria Bioscience has a consensus price target of $11.00, suggesting a potential upside of 404.59%. Given Lexaria Bioscience's higher possible upside, analysts plainly believe Lexaria Bioscience is more favorable than Kiora Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiora Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Lexaria Bioscience 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor KPRX or LEXX? In the previous week, Kiora Pharmaceuticals had 1 more articles in the media than Lexaria Bioscience. MarketBeat recorded 2 mentions for Kiora Pharmaceuticals and 1 mentions for Lexaria Bioscience. Kiora Pharmaceuticals' average media sentiment score of 0.84 beat Lexaria Bioscience's score of -1.00 indicating that Kiora Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Kiora Pharmaceuticals Positive Lexaria Bioscience Negative SummaryKiora Pharmaceuticals beats Lexaria Bioscience on 10 of the 17 factors compared between the two stocks. Ad Porter & CompanyViral Trump video releasedPorter Stansberry’s latest video is going viral… In this bombshell exposé, famed economist Porter Stansberry reveals what happened during his trip to Mar-a-Lago, his meeting with Donald Trump, and the 10 urgent money moves to make before Jan 20 inauguration. Your link to watch Trump’s Secret Stocks is here. Get Kiora Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPRX vs. The Competition Export to ExcelMetricKiora PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.93M$6.58B$5.15B$9.00BDividend YieldN/A2.96%4.96%4.20%P/E RatioN/A10.6786.9916.99Price / Sales0.62194.101,132.84118.37Price / CashN/A57.1543.2737.84Price / Book0.465.104.804.90Net Income-$12.51M$150.98M$120.16M$225.21M7 Day Performance0.61%0.88%0.72%3.16%1 Month Performance1.53%-6.73%15.78%1.84%1 Year Performance-29.60%5.86%28.08%16.29% Kiora Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPRXKiora Pharmaceuticals3.6903 of 5 stars$3.31+0.6%$10.00+202.1%-30.0%$9.93M$16M0.0010Short Interest ↓LEXXLexaria Bioscience2.8784 of 5 stars$2.19-1.8%$11.00+402.3%+83.2%$38.22M$460,000.00-4.667Short Interest ↑ATNMActinium Pharmaceuticals1.3799 of 5 stars$1.23-5.0%$7.40+504.1%-76.4%$38.22M$81,000.00-0.8849SCYXSCYNEXIS1.4558 of 5 stars$1.00+0.0%N/A-55.2%$37.95M$8.57M-1.3560Short Interest ↓CALCCalciMedica2.983 of 5 stars$2.80+1.4%$19.33+590.5%-0.3%$37.75MN/A-2.5930Short Interest ↑RLYBRallybio2.5917 of 5 stars$0.91-4.2%$9.75+971.5%-61.8%$37.75M$598,000.00-0.5740LUMOLumos Pharma3.2247 of 5 stars$4.34flat$8.63+98.7%+36.5%$37.54M$2.21M-1.0130High Trading VolumeOCXOncoCyte2.9502 of 5 stars$2.21+0.9%$4.42+99.8%-14.9%$37.21M$709,000.000.00120Insider TradeShort Interest ↑Gap DownBIVIBioVie1.8018 of 5 stars$2.06+8.4%$3.00+45.6%+69.0%$36.60MN/A-0.1810Short Interest ↑TPSTTempest Therapeutics2.0578 of 5 stars$0.82+15.6%$20.00+2,331.0%-80.9%$35.90MN/A-0.5420Short Interest ↑OKYOOKYO Pharma2.6724 of 5 stars$1.05-0.9%$7.00+566.7%-34.5%$35.53MN/A0.007 Related Companies and Tools Related Companies Lexaria Bioscience Competitors Actinium Pharmaceuticals Competitors SCYNEXIS Competitors CalciMedica Competitors Rallybio Competitors Lumos Pharma Competitors OncoCyte Competitors BioVie Competitors Tempest Therapeutics Competitors OKYO Pharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KPRX) was last updated on 12/30/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored3 CENT Crypto to Explode December 16th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredViral Trump video releasedPorter Stansberry’s latest video is going viral… In this bombshell exposé, famed economist Porter Stansberr...Porter & Company | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored>>>RE: Buy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiora Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiora Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
